Overview

A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia

Status:
COMPLETED

Trial end date:
2024-06-07

Target enrollment:

Participant gender:

Summary

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of SAL003, a recombinant fully human anti-PCSK9 monoclonal antibody, in combination with a stable dose of atorvastatin in patients with hypercholesterolemia and mixed dyslipidemia.

Phase:

PHASE2

Details

Lead Sponsor:

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Collaborator:

Salubris (Chengdu) Biotechnology Co., Ltd.

Treatments:

Atorvastatin